Pacira BioSciences, Inc. (PCRX)
USD 19.19
(-3.23%)
USD 19.19
(-3.23%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | 154.64 Million | 145.27 Million | 125.71 Million | 77.03 Million | 70.52 Million | 48.87 Million |
| Net Income | 41.95 Million | 15.9 Million | 41.98 Million | 145.52 Million | -11.01 Million | -471 Thousand |
| Depreciation & Amortization | 75.57 Million | 91.5 Million | 28.54 Million | 19.9 Million | 19.57 Million | 13.16 Million |
| Deferred income taxes | 15.61 Million | -7.94 Million | 10.87 Million | -126.61 Million | 5.32 Million | 919 Thousand |
| Stock-based compensation | 47.89 Million | 48.09 Million | 42.24 Million | 39.92 Million | 33.65 Million | 31.72 Million |
| Change in working capital | -45.77 Million | -16.43 Million | -18.67 Million | -24.38 Million | -8.77 Million | -10.85 Million |
| Other non-cash items | 19.38 Million | 14.15 Million | 20.74 Million | 22.68 Million | 31.75 Million | 14.38 Million |
| Investing Cash Flow | 77.54 Million | -225.18 Million | -20.79 Million | -277.6 Million | -128.48 Million | 20.57 Million |
| Investments in PPE | -15.16 Million | -30.07 Million | -45.86 Million | -37.8 Million | -10.15 Million | -14.51 Million |
| Acquisitions | -92.7 Million | -32 Million | -437.22 Million | -1.16 Million | -119.31 Million | -7 Million |
| Investment purchases | -144.36 Million | -400.68 Million | -611.48 Million | -546.51 Million | -318.48 Million | -363.25 Million |
| Sales/Maturities of investments | 237.06 Million | 237.57 Million | 1.07 Billion | 307.87 Million | 319.46 Million | 405.18 Million |
| Other Investing Activities | 92.7 Million | -32 Million | -4 Million | -239.8 Million | -638 Thousand | 157 Thousand |
| Financing Cash Flow | -183.03 Million | -401.52 Million | 380.69 Million | 222.3 Million | 3.67 Million | 8.95 Million |
| Debt repayment | -187.67 Million | -427.69 Million | -359.2 Million | -209.88 Million | -338 Thousand | - |
| Dividends payments | - | - | -2.67 Million | -1.61 Million | -4.31 Million | - |
| Common Stock Repurchased | -106 Thousand | 2.95 Million | 2.81 Million | -33.08 Million | - | - |
| Common Stock Issuance | 4.75 Million | 27.34 Million | 26.65 Million | 47.76 Million | 10.87 Million | 8.95 Million |
| Other Financing Activities | -106 Thousand | 26.16 Million | -5.16 Million | 419.12 Million | 4 Million | 8.95 Million |
| Accounts receivables | -7.15 Million | -2.07 Million | -10.43 Million | -5.51 Million | -8.52 Million | -5.99 Million |
| Accounts payables | 916 Thousand | 6.27 Million | -10.26 Million | -3.31 Million | -1.82 Million | -573 Thousand |
| Inventory | -8.28 Million | 2.48 Million | -4.46 Million | -6.35 Million | -8.02 Million | -7.15 Million |
| Other working capital | -31.24 Million | -23.11 Million | 6.48 Million | -9.2 Million | 9.6 Million | 2.87 Million |
| Cash at beginning of period | 104.13 Million | 585.57 Million | 99.95 Million | 78.22 Million | 132.52 Million | 54.12 Million |
| Cash at end of period | 153.29 Million | 104.13 Million | 585.57 Million | 99.95 Million | 78.22 Million | 132.52 Million |
| Capital Expenditure | -15.16 Million | -30.07 Million | -45.86 Million | -37.8 Million | -10.15 Million | -14.51 Million |
| Effect of forex changes on cash | 105.49 Million | - | - | - | - | - |
| Net cash flow / Change in cash | 49.15 Million | -481.43 Million | 485.62 Million | 21.72 Million | -54.29 Million | 78.4 Million |
| Free Cash Flow | 139.48 Million | 115.19 Million | 79.85 Million | 39.23 Million | 60.36 Million | 34.35 Million |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 FY | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | 18.88 Million | 8.97 Million | 24.87 Million | 41.95 Million | 10.85 Million | 25.76 Million |
| Depreciation & Amortization | 18.86 Million | 18.42 Million | 18.48 Million | 75.57 Million | 18.43 Million | 19.05 Million |
| Deferred income taxes | 12.53 Million | 3.46 Million | 6.6 Million | 15.61 Million | 4.91 Million | 11.44 Million |
| Stock-based compensation | 12.52 Million | 13.15 Million | 12.42 Million | 47.89 Million | 12.53 Million | 10.95 Million |
| Change in working capital | -4.38 Million | 8.1 Million | -15.64 Million | -45.77 Million | -8.2 Million | -6.21 Million |
| Other non-cash items | 45.11 Million | 42.46 Million | 854 Thousand | 19.38 Million | 5.9 Million | -17.5 Million |
| Investing Cash Flow | -15.21 Million | -15.53 Million | 8.37 Million | 77.54 Million | -4.34 Million | 7.32 Million |
| Investments in PPE | -1.59 Million | -2.83 Million | -1.79 Million | -15.16 Million | -3.39 Million | -3.4 Million |
| Acquisitions | - | - | -10.17 Million | -92.7 Million | 948 Thousand | -10.73 Million |
| Investment purchases | -49.72 Million | -56.05 Million | -25.92 Million | -144.36 Million | -42.17 Million | -22.77 Million |
| Sales/Maturities of investments | 36.1 Million | 43.36 Million | 36.09 Million | 237.06 Million | 41.22 Million | 33.5 Million |
| Other Investing Activities | -13.62 Million | -12.69 Million | 10.17 Million | 92.7 Million | -948 Thousand | 10.73 Million |
| Financing Cash Flow | 24.98 Million | -2.81 Million | -1.77 Million | -183.03 Million | -27.78 Million | 440 Thousand |
| Debt repayment | -48.99 Million | -2.81 Million | -2.81 Million | -187.67 Million | -27.81 Million | -2.81 Million |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | -25 Million | -4000.00 | -106 Thousand | -106 Thousand | - | - |
| Common Stock Issuance | 1.36 Million | - | 1.13 Million | 4.75 Million | 25 Thousand | 3.25 Million |
| Other Financing Activities | -378 Thousand | -4000.00 | -106 Thousand | -106 Thousand | -27.78 Million | 440 Thousand |
| Accounts receivables | -3.14 Million | 3.91 Million | -8.59 Million | -7.15 Million | 2.12 Million | -5.87 Million |
| Accounts payables | 9.74 Million | -6.97 Million | -1.07 Million | 916 Thousand | -7.69 Million | 7.05 Million |
| Inventory | -6.65 Million | 7.57 Million | -7.83 Million | -8.28 Million | -4.39 Million | 847 Thousand |
| Other working capital | -4.33 Million | 3.59 Million | 1.85 Million | -31.24 Million | 1.76 Million | -8.23 Million |
| Cash at beginning of period | 184.05 Million | 153.29 Million | 99.11 Million | 104.13 Million | 86.81 Million | 35.54 Million |
| Cash at end of period | 247.05 Million | 184.05 Million | 153.29 Million | 153.29 Million | 99.11 Million | 86.81 Million |
| Capital Expenditure | -1.59 Million | -2.83 Million | -1.79 Million | -15.16 Million | -3.39 Million | -3.4 Million |
| Effect of forex changes on cash | - | - | -2.56 Million | 105.49 Million | 29.51 Million | -6.08 Million |
| Net cash flow / Change in cash | 63 Million | 30.75 Million | 54.17 Million | 49.15 Million | 12.3 Million | 51.26 Million |
| Free Cash Flow | 51.64 Million | 46.26 Million | 45.78 Million | 139.48 Million | 41.04 Million | 40.09 Million |
096770
ADCON
8079
RITM-PC
300069
2022